Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Intensity Therapeutics Inc (NASDAQ: INTS) closed the day trading at $0.26 down -0.72% from the previous closing price of $0.26. In other words, the price has decreased by -$0.72 from its previous closing price. On the day, 2.87 million shares were traded. INTS stock price reached its highest trading level at $0.2617 during the session, while it also had its lowest trading level at $0.243.
Ratios:
For a better understanding of INTS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.40 and its Current Ratio is at 1.40. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INTS now has a Market Capitalization of 12798570 and an Enterprise Value of 10186361.
Stock Price History:
The Beta on a monthly basis for INTS is 3.53, which has changed by -0.9216216 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, INTS has reached a high of $3.44, while it has fallen to a 52-week low of $0.19. The 50-Day Moving Average of the stock is -4.96%, while the 200-Day Moving Average is calculated to be -74.93%.
Shares Statistics:
Over the past 3-months, INTS traded about 5.02M shares per day on average, while over the past 10 days, INTS traded about 8786310 shares per day. A total of 49.06M shares are outstanding, with a floating share count of 43.80M. Insiders hold about 10.72% of the company’s shares, while institutions hold 4.03% stake in the company. Shares short for INTS as of 1759190400 were 865945 with a Short Ratio of 0.17, compared to 1756425600 on 670859. Therefore, it implies a Short% of Shares Outstanding of 865945 and a Short% of Float of 1.8399999999999999.
Earnings Estimates
. The current rating of Intensity Therapeutics Inc (INTS) is the result of assessments by 2 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.35 and -$0.38 for the fiscal current year, implying an average EPS of -$0.37. EPS for the following year is -$0.37, with 2.0 analysts recommending between -$0.24 and -$0.5.
